July 15, 2025

Supplementary Figure S1 from First-in-Human Phase I/IIa Study of the First-in-Class CDK2/4/6 Inhibitor PF-06873600 Alone or with Endocrine Therapy in Patients with Breast Cancer

View Full Paper

Ask AI

Bookmark

MAIN FINDING: CDK2/4/6 inhibitor PF-06873600 shows promising changes in tumor biomarkers among patients with breast cancer.
KEY EVIDENCE: Data indicate significant changes from baseline in tumor biomarkers following both monotherapy and combination treatment.
APPROACH: The study involved a phase I/IIa design assessing a first-in-class therapy in patients with breast cancer.
SIGNIFICANCE: Findings may support further development of combination treatment strategies in breast cancer therapy.

Discussion

No takes yet. Share an insight, caveat, or question.

Phase I/IIa trial demonstrates changes in tumor biomarkers from baseline in patients with breast cancer, suggesting potential in combination therapy.

Yap et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

Phase I/IIa trial demonstrates changes in tumor biomarkers from baseline in patients with breast cancer, suggesting potential in combination therapy.